Two immunotoxins were constructed by chemically coupling the monoclonal antibody C242 to Pseudomonas exotoxin A (PE) or a modified form, NlysPE40, that lacks the cell binding domain of PE. Monoclonal antibody C242 recognizes a specific sialylated carbohydrate epitope on a high molecular weight membrane glycoprotein present on cells ofhuman colon, pancreatic, and cervical cancers. C242-PE and C242-NlysPE40 were very cytotoxic for cells expressing this antigen with 50% inhibition of protein synthesis occurring on Colo2O5 cells at 0.2 ng/ ml (0.9 pM) for C242-PE and 6.0 ng/ml (31 pM) for C242-NlysPE40. The two immunotoxins also exhibited a strong antitumor effect on a human colon cancer xenograft grown in nude mice. The specificity and potency of these two C242 immunotoxins warrant their further development for the treatment of cancer. (J. Clin. Invest. 1992. 90:405411.) Key words: colon cancer * immunotoxins * Pseudomonas exotoxin A * solid tumor therapy
Introduction
A number of human cancers, such as those in the colon and pancreas, are very resistant to presently available methods of treatment. In the search for an alternative or supplemental therapy more than a decade ofresearch has revived a simple idea of specific targeting of toxic agents to cells causing disease (1) . One of the possible ways to accomplish this goal is to find an "identification marker" on cancer cells in the form ofa unique antigen not shared with normal tissues. By means of hybridoma monoclonal antibody technology, this antigen could be used to produce an antibody directed specifically against cells expressing the marker (2) . Then, the monoclonal antibody coupled, for example, to a bacterial toxin would selectively bind to the cancer cells and deliver the lethal toxin. This concept has been reviewed in several recent articles (1, 3, 4) . However, for this therapy to be successful there are several problems to be solved. One is to produce an antibody fulfilling the mini-mum criteria ofspecificity. Other problems revolve around the toxin portion of the immunotoxin, namely, for the toxin portion to have low nonspecific toxicity and low immunogenicity (5, 6) .
We have been working on developing immunotoxins based on Pseudomonas exotoxin A,' (PE) as reported in Pastan and FitzGerald (4) . PE is a 66-kD single-chain protein composed of three structural and functional domains: I, II, and III (5, 7) . Domain I contains the cell receptor-binding sequence, domain II takes part in translocation and proteolytic cleavage of the toxin, and domain III catalyzes the ADP-ribosylation and inactivation of elongation factor 2 (4). To construct an immunotoxin, PE can be used either as the native molecule or in a truncated form, called PE40. PE40 lacks domain I, the cellbinding domain, but retains all the functions ofdomains II and III (8, 9) . The efficacy of immunotoxins made with PE or PE40 has been demonstrated in vitro on cultured cells as well as in mice bearing intraperitoneal and subcutaneous tumors (9) (10) (11) .
Recently, the monoclonal antibody C242 that reacts with human colon carcinoma cells was isolated. (17) served to provide the toxin with maleimides ready to react with thiols present on the derivatized antibody. C242 exhibited 0.8, 1.6, and 2.4 thiols per mole when subjected to 5-, 10-, and 25-fold molar excess of IT, respectively. This reaction was performed in 0.1 M NaH2PO4/ 1 mM EDTA, pH 8.0, in 1 mM ,B-2-mercaptoethanol at 37°C for 30 min. The number of sulfhydryl groups was determined using Ellman's reagent (18) . Derivatized antibody was separated from the reactants by gel filtration on Sephadex G-25 (PD10 column, Pharmacia Inc.) equilibrated with 0.1 M NaH2PO4/ 5 mM EDTA, pH 6.0, C242 with 1.6 thiols per mole gave the highest yield of conjugate.
PE and NlysPE40 were derivatized with threefold molar excess of SMCC in 0.1 M NaH2PO4, pH 7.0, during a 1-h incubation at room temperature. Toxins were separated from the crosslinker on a PD10 column. Derivatized C242 and PE or NlysPE40 were mixed together in a 1:3 molar ratio and left at room temperature for an overnight incubation. To block unreacted groups, iodoacetamide was added in a final concentration of 1 mM for 20 min at room temperature. Then, the immunotoxins were purified by the two-step liquid chromatography, as previously described (9 (5) . ID50 indicated the concentration of immunotoxin at which the isotope incorporation fell by 50% when compared to nontreated cells. For the cytotoxicity assay, the cells were plated at 2 x I04 per well in 24-well plates 24 h before addition of immunotoxin. The cells were incubated for 3, 4, and 7 d and viable cells were identified by methylene-blue staining (5) .
Binding studies. We attempted to determine the binding ability of C242 immunotoxins as compared to the antibody alone. To this end, we labeled C242 with 1251 (New England Nuclear, Boston, MA) using a lactoperoxidase method, exactly as described (19) . C242 (8 Mg) was mixed with 0.5 mCi of the isotope. Labeled antibody was separated from unreacted isotope on a PDlO column. The fractions collected from gel filtration were enriched in human serum albumin (HSA) to 0.2% (wt/vol) final concentration. We estimated the binding ability of labeled C242 according to a previously described protocol (20) (9) .
Tumors from several treated and nontreated animals were removed from the mice either for immunoperoxidase histochemistry or for preparation ofthe primary culture ofColo2O5 cells derived from tumors. In addition, some animals bearing large tumors (> 450 mm3) were bled and their sera were checked for the presence ofinhibitory substances by incubating serum samples with different immunotoxin concentrations and then testing the mixture on Colo2O5 cells and measuring [3H]leucine incorporation. Blood was withdrawn from the orbital vein under methoxyflurane anesthesia.
Results
In the present investigation, we used PE and PE40 to make chemical conjugates with the anti-human colorectal cancer monoclonal antibody, C242. The form of PE40 used in this study, termed NlysPE40, has 11 amino acids (MLEGTKL-MAEE; Fig. 1 ) preceding Gly2 " of PE; domain II of PE begins at amino acid 253. This sequence was confirmed by the amino acid analysis using repeated cycles of the Edman degradation reaction. The lysine residue introduced at the amino terminus of PE40 is believed to facilitate coupling to antibody (9) . We have chosen this form of PE40 because expression levels are higher than with another lysPE40 version (9) , and because it is found primarily in the periplasm, easing the process of toxin purification. In addition, immunotoxins made with NlysPE40
and MAbs HB2 1 (see below) or C242 exhibited similar cytotoxic activities as immunotoxins made with the previously described form of lysPE40 (9) . Cytotoxicity ofC242 immunotoxins. To evaluate the cytotoxic activities of C242-PE and C242-NlysPE40 we tested various human cancer cell lines with different amounts of the C242-reactive antigen on their surface (Table I) (9) . Colo205 cells, which uniformly express the C242 antigen, were very responsive to C242 immunotoxins; the ID50 for C242-PE was found to be 0.2 ng/ml and for C242-NlysPE40 it was 6.0 ng/ml. These values are comparable to those obtained with immunotoxins made by using the MAb HB21 that reacts with the human transferrin receptor. C242 antigen density and uniformity, as measured by immunofluorescence, was less on several other tested cell lines, such as HT29 (Table I) , KATO III, and DU145 (not shown), and absent on ovarian (OVCAR-3, OV-CAR-4, 1847, 2780), breast (MCF-7, SKOV-3), cervical (KB), and gastric (AGS) carcinoma cell lines. This antigen was also completely absent on human epidermoid carcinoma A431 cells (Table I ). The relative amount ofthe C242-reactive antigen on the cell surface was related to the susceptibility of these cells to treatment with C242 immunotoxins, i.e., the greater amount of antigen, the greater response to C242-PE or C242-NlysPE40. A431 cells were not killed by C242 immunotoxins, however, they were very responsive to HB21 conjugates, as expected (9) . These results demonstrate that C242 immunotoxins specifically target cells which express the appropriate antigen. To determine if exposure to C242 immunotoxin results not only in the inhibition ofprotein synthesis but also in cell death, we performed a cytotoxicity assay. C242-NMysPE40 added to Colo2O5 cells killed 50% of these cells at a concentration of 0.5 ng/ml and > 95% ofcells at a concentration of 5.0 ng/ml after 3 d of incubation. To ascertain further the specificity of C242 conjugates on cells expressing the C242 antigen, we employed the competition assays illustrated in Fig. 2 A. C242 MAb alone did not have any effect on the protein synthesis of Colo2O5 cells at concentrations up to 50 ,g/ml. However, C242, added at a 500-fold excess was able to block completely the cytotoxic effect of C242-NlysPE40 and to diminish it by 50% when added at a 50-fold excess. On the other hand, C242 did not interfere with the cytotoxic effect ofHB2 I-MysPE40. Colo2O5 cells were also subjected to treatment with B3-NlysPE38 conjugates with or without MAb C242 (Fig. 2 B) . B3 immunotoxins did not affect protein synthesis at concentrations up to 1 ug/ml, whether or not C242 was present. These results indicate a highly specific action of the C242 conjugates.
We also measured to what extent the affinity of the C242 MAb for the C242-reactive antigen had been changed when chemically attached to PE. Binding efficiencies of C242, C242 modified with IT and C242-NlysPE40 to Colo2O5 cells were established in a competition assay with '25I-C242. C242 displaced the labeled antibody with an IC50 of0.8 X 10-8 M. C242 antibodies which had thiol groups introduced into the molecule demonstrated a similar competitiveness to the nonderivatized antibody (data not shown). This suggests that the antibody binding region was not altered by reaction with the thiolating agent which is the first step in the production of immunotoxin. However, C242-NMysPE40 competed for the binding of '251-C242 less efficiently than the antibody alone (Fig. 4A) . This treatment markedly inhib- gate every second day. C242-NlysPE40 (Fig. 4 B) and C242-PE 40 - (Fig. 4 C) (Fig. 4 - (Fig. 4 D) . These results with an IC50 threefold higher than that for C242 (Fig. 3) . Thus, C242-NlysPE40 has decreased binding to the C242 antigen when compared to the antibody alone. Although the antitumor effect of C242 conjugates was very significant, it did not cause a complete regression oftumors, as was previously observed using immunotoxins that react with A431 tumors (9, 11) . To understand this discrepancy, we performed several control experiments. We treated mice bearing Colo2O5 tumors with HB2 1-PE immunotoxin which has a higher cytotoxic activity in culture on Colo2O5 cells than C242-PE (Table I) , to see whether it would exert a better antitumor effect. We found that HB21-PE did not evoke a complete regression of Colo2O5 tumors (data not shown). Thus, the failure to cause complete regression ofColo2O5 tumors was not unique to C242 immunotoxins. We also took into account the fact that the C242 antigen is a shed antigen in mice xenografted with Colo2O5 cells.2 Therefore, it was important to establish if there was an abundant amount of circulating C242 antigen blocking the action of immunotoxin. The results of an experiment that addressed at this possibility are shown in Table  II . Various concentrations of C242-MysPE40 were incubated with sera of mice bearing large Colo2O5 tumors (> 450 mm3). Then, the preincubated toxin was added at various concentrations to Colo2O5 cells and a protein synthesis inhibition assay was performed. There was no significant inhibition ofimmunotoxin activity by preincubation with mouse sera. Thus, it seems very unlikely that the blood of mice with Colo2O5 tumors contains sufficient C242 antigen to neutralize C242 immunotoxins.
To determine whether Colo2O5 cells which form the tumor become C242 antigen-negative, we removed tumors from the same mice from which the blood was withdrawn for the neutralizing study and verified the expression of the C242 antigen by immunoperoxidase histochemistry. C242 antigen as well as transferrin receptors were strongly and uniformly localized in these tumors (data not shown). To determine ifthe tumor cells had become resistant to the immunotoxins by a mechanism different from antigen depletion, we prepared primary cultures from treated tumors and subjected these cells to treatment with immunotoxins. The results ofthis experiment are presented in Fig. 5. C242 and HB21 immunotoxins had approximately the same ID5o's on the reisolated tumor cells (Fig. 5) as on the original cell line that produced the tumors (Table I) Antitumor activity of C242-PE and C242-NlysPE40. We were able to treat nude mice bearing human colon cancer xenografts with very similar doses of C242 immunotoxins as with other immunotoxins used in our laboratory (9, 1 1). Using these doses (0. 5,gg for C242-PE and 20,gg for C242-NlysPE40)
we achieved a significant degree of antitumor activity by i.p. administration. C242 immunotoxins were active when they were administered both 1 and 8 d after tumor implantation when the tumors had grown to form a detectable solid tumor. The injections of immunotoxins were repeated four times every other day which was well tolerated by the animals. However, we did not observe complete tumor regression as seen previously with B3-PE or B3-lysPE40 (11) , and several factors may account for this result. Colo205 tumor model in mice. In previous studies we have found that increasing the dose of an immunotoxin increases the antitumor activity (9, 11) . Unexpectedly, in this study in- creasing the dose of C242-NlysPE40 from 20 to 50,ug per dose did not result in an increase in activity. We ruled out the possibility that the human cells had lost their response to C242-NlysPE40 by isolating cells from treated tumors and showing both that they had surface antigen and responded normally to 
